Social Survey Research Information Co., Ltd. PatientsMap 2022 US version now available - ssri | Social Survey Research Information Co., Ltd.

February 02nd, 23
Social Survey Research Information Co., Ltd.

Social Survey Research Information Co., Ltd. and M3, Inc. conducted an analysis of manufacturers' activities based on the PatientsMap 2022 US version, which went on sale at the end of December 2022.

The survey asked about the status of activities, namely "awareness of sales rep visits," "awareness of online meetings," and "awareness of e-detailing."
(Table 1) shows the top 10 manufacturers in terms of awareness rate for each category, and (Table 2) shows the ranking of Japanese companies in the U.S.

In the U.S., Pfizer, Abbott, and AstraZeneca ranked high in each category. The awareness rates of sales rep visits and e-detailing were about the same among these top manufacturers.
With regard to the awareness of online meetings, Pfizer (8%) and Abbott (7%) ranked at the top in the U.S., which was only about half that of sales rep visits.
In the U.S., Pfizer topped the list at 33%, which was followed by Abbott at 31%, AstraZeneca at 29%, Merck at 25%, and AbbVie at 24% in terms of reaching physicians using one of these three methods.

Looking at Japanese companies in the U.S., Takeda, Astellas, and Otsuka Pharmaceutical were in higher ranks, in this order, in terms of all categories.
Takeda has reached 13% of physicians using one of these three methods, and the percentages for Astellas and Otsuka Pharmaceutical were 8% and 6%, respectively. Takeda ranked 17th out of the 54 companies surveyed, which was the highest among the Japanese companies.

It will be necessary to pay attention to changes in how manufacturers will utilize "sales rep visits," "online meetings," and "e-detailing" in anticipation of "coexisting with COVID-19" in the future.

(Table 1) U.S. manufacturer activities: Rank among 54 companies surveyed.

n=6085

	Awareness of sales rep visits		Awareness of online meetings		Awareness of e-detailing		Any of the methods
rank	Manufacturers	％	Manufacturers	％	Manufacturers	％	Manufacturers	％
1	Abbott	17.8%	Pfizer	8.2%	Pfizer	16.7%	Pfizer	32.5%
2	Pfizer	17.3%	Abbott	7.2%	Abbott	14.6%	Abbott	31.2%
3	AZ	15.5%	AZ	6.8%	AZ	14.3%	AZ	29.2%
4	AbbVie	14.7%	AbbVie	6.0%	J&J	12.7%	Merck	25.0%
5	Merck	13.5%	Merck	5.9%	Merck	12.4%	AbbVie	24.3%
6	Eli Lilly	13.3%	J&J	5.7%	Eli Lilly	11.6%	J&J	23.9%
7	GSK	12.3%	Eli Lilly	5.7%	GSK	10.8%	Eli Lilly	23.7%
8	J&J	11.9%	GSK	5.6%	AbbVie	10.4%	GSK	22.5%
9	Allergan	11.5%	Allergan	5.3%	Moderna	9.6%	Allergan	20.7%
10	Sanofi	11.0%	Sanofi	5.3%	Allergan	9.4%	Sanofi	20.0%

(Table 2) Japanese company activities in the U.S.: Rank among 54 companies surveyed.

n=6085

	Awareness of sales rep visits		Awareness of online meetings			Awareness of e-detailing			Any of the methods
rank	Manufacturers	％	rank	Manufacturers	％	rank	Manufacturers	％	rank	Manufacturers	％
17	Takeda	6.5%	16	Takeda	3.4%	22	Takeda	5.9%	17	Takeda	12.5%
27	Astellas	3.3%	33	Astellas	1.8%	31	Astellas	4.1%	31	Astellas	8.1%
37	Otsuka	2.2%	36	Otsuka	1.7%	40	Otsuka	3.2%	37	Otsuka	6.0%
38	Daiichi Sankyo	2.2%	44	Daiichi Sankyo	1.3%	41	Eisai	3.1%	38	Daiichi Sankyo	5.9%
42	Eisai	1.7%	45	Eisai	1.3%	42	Daiichi Sankyo	3.0%	44	Eisai	5.5%
49	Takeda Oncology	1.1%	48	Takeda Oncology	1.2%	47	Takeda Oncology	2.8%	47	Takeda Oncology	4.6%
52	Mitsubishi Tanabe	0.8%	50	Mitsubishi Tanabe	1.0%	50	Mitsubishi Tanabe	2.6%	51	Mitsubishi Tanabe	3.9%

What is PatientsMap?
PatientsMap is a large database that surveys, with the cooperation of physicians, about 400 diseases in terms of physician coverage, number of patients, unmet medical needs (diseases for which new drugs are desired, reasons for wanting new drugs, and percentage of patients for whom administering new drugs would be considered), and the activities of real sales reps (in-person) and e-detailing activities of pharmaceutical companies. The same survey frame has been used continuously for more than 10 years since 2010.

Overview of PatientsMap 2022 United States of America Version (2022US)

The PatientsMap 2022US conducted a study on 38,000 doctors who are members of M3 Global Research.

Target respondents:	:	M3 Global Research member doctors
Method	:	Online survey
Fieldwork period	:	December 27, 2022 to January 24, 2022
Sample size collected	:	6,085 samples
Number of conditions surveyed	:	410 diseases
Survey item:	:	Total number of patients (in the past month) Number of patients seen by condition (in the past month) Number of patients who were prescribed drugs by condition (in the past month) Need for new therapy Manufacturers that you have had a face-to-face meeting with one of their sales reps (in the past month) Manufacturers that you have had a remote meeting with one of their sales reps (in the past month) Manufacturer that have provided you with information via the Internet (in the past month) Reliable manufacturers

Contact Information

Social Survey Research Information Co., Ltd.
e-mail	:	patientsmap@ssri.com